SELLAS Life Sciences Group (SLS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.05
- Surprise
- —
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Solaris Resources Receives Final $50 Million Tranche of $200 Million Funding Package — fiscal.ai, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates SLS Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $32.50 vs price $8.42 — ratio 3.9×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
- Momentum score 3.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.42
- Price target
- $12.19
- Stop
- $7.83
- Upside to target
- +44.8%
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
SLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.70B
- P/E (fwd)
- -84.2
- 52-week range
- $1.39–$15.88
- Off 52-week high
- 47.0%
- RSI (14)
- 31
- Volume vs avg
- 0.50×
- Score today
- 4.9/10